Revenue: As of FY2025 Q3, the actual value is USD 0, missing the estimate of USD 727.27 K.EPS: As of FY2025 Q3, the actual value is USD -0.65, missing the estimate of USD -0.5759.EBIT: As of FY2025 Q3, the actual value is USD -62.82 M.<h3>Segment Revenue</h3><ul><li>Collaboration Revenue: For the nine months ended September 30, 2025, collaboration revenue was $6.941 million, compared to $6.303 million for the same period in 2024, reflecting an increase of $0.638 million.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The net loss for the nine months ended September 30, 2025, was - $142.494 million, compared to - $212.714 million for the same period in 2024, showing a reduction in net loss by $70.220 million.</li><li>Research and Development Expenses: Increased by $44.864 million, from $81.652 million for the nine months ended September 30, 2024, to $126.516 million for the same period in 2025.</li><li>General and Administrative Expenses: Increased by $9.168 million, from $22.509 million for the nine months ended September 30, 2024, to $31.677 million for the same period in 2025.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was - $142.966 million, compared to - $68.734 million for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: For the nine months ended September 30, 2025, net cash provided by investing activities was $64.802 million, compared to net cash used of - $94.821 million for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $207.562 million, compared to $220.444 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Share-Based Compensation Expense: Total share-based compensation expense for the nine months ended September 30, 2025, was $17.797 million, compared to $10.278 million for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Immunome, Inc. plans to continue advancing its pipeline, which includes three clinical assets and three preclinical assets. The company expects to report topline data from the Phase 3 trial of Varegacestat in the second half of 2025 and plans to initiate a Phase 1 trial for IM-3050 in early 2026.</li><li>Non-Core Business: The company is investing in discovery efforts to expand its pipeline, focusing on additional ADC programs and developing a diverse pipeline of ADCs.</li></ul>

Immunome | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 0